Skip to main content
OpenTrials
Completed

NCT Number: NCT01390922

Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)

The objective of this post-marketing surveillance study is to collect safety, efficacy and usage data on botulinum injection in subjects with upper or lower limb spasticity on the long-term use in clinical practice and to identify the factors affecting the safety or efficacy.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with upper or lower limb spasticity
  • Subjects must use botulinum injection for the first time

Exclusion criteria

  • Not applicable

Treatment and study plan

Botulinum Toxin Type A

Drug

Botulinum Toxin Type A

Primary outcomes

  1. The number of adverse events in Japanese subjects with spasticity treated with botulinum injection

    Time frame: 1 year

  2. Occurence of adverse events at remote sites

    Time frame: 1 year

  3. Occurence of adverse events associated with pulmonary function

    Time frame: 1 year

  4. Onset status of adverse events associated with convulsion

    Time frame: 1 year

  5. Onset status of adverse events associated with accidents such as fall

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Special Drug Use Investigation for Botox® (Botulinum) Spasticity

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Jul 11, 2011
Registry last updated
Mar 27, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.